Aspire Biopharma Holdings Inc Financials
This page shows Aspire Biopharma Holdings Inc (ASBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aspire Biopharma’s reported business is development-driven and financing-dependent, with tiny revenue but cash needs carried by new capital.
In FY2025, development spending dwarfed commercial activity: revenue was only$6.2K while R&D reached$924K , and the year-end cash balance of$1.0M was smaller than the$4.9M operating cash burn. That combination means the company was functioning more like a funded research program than a self-sustaining seller of product.
The cash balance overstates liquidity because current liabilities of
The balance sheet has been reset rather than compounded: total assets moved from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Aspire Biopharma Holdings Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aspire Biopharma Holdings Inc's current ratio of 0.17 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Key Financial Metrics
Earnings & Revenue
Aspire Biopharma Holdings Inc generated $6K in revenue in fiscal year 2025.
Aspire Biopharma Holdings Inc earned $-16.38 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 762.1% from the prior year.
Cash & Balance Sheet
Aspire Biopharma Holdings Inc held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.
Aspire Biopharma Holdings Inc had 4M shares outstanding in fiscal year 2025. This represents an increase of 412.1% from the prior year.
Margins & Returns
Aspire Biopharma Holdings Inc's gross margin was -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Capital Allocation
Aspire Biopharma Holdings Inc invested $924K in research and development in fiscal year 2025. This represents an increase of 540.0% from the prior year.
ASBP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2K | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $1K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $884 | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $208K-41.1% | $353K+34.1% | $263K | N/A | $7K-33.3% | $11K0.0% | $11K |
| SG&A Expenses | N/A | $513K+29.6% | $396K | N/A | N/A | $192K+121.7% | $86K-34.9% | $133K |
| Operating Income | N/A | -$1.1M | N/A | N/A | N/A | -$215K | N/A | N/A |
| Interest Expense | N/A | $1.5M+180.4% | $528K+82.1% | $290K | N/A | N/A | N/A | $183K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $1K | N/A | N/A |
| Net Income | N/A | -$1.9M+6.6% | -$2.0M | N/A | N/A | -$216K-123.1% | -$97K+58.0% | -$231K |
| EPS (Diluted) | N/A | $-0.04 | N/A | N/A | N/A | $-0.01 | N/A | N/A |
ASBP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3M-45.4% | $2.4M+142.9% | $989K-49.7% | $2.0M+1228.1% | $148K-97.8% | $6.7M-3.0% | $6.9M-66.0% | $20.2M |
| Current Assets | $1.3M-45.4% | $2.4M+142.9% | $989K-49.7% | $2.0M+1228.1% | $148K+139.4% | $62K-82.0% | $343K+423.0% | $66K |
| Cash & Equivalents | $1.0M-48.5% | $1.9M+844.7% | $206K-84.7% | $1.3M+36964.2% | $4K-78.0% | $17K-15.6% | $20K-58.5% | $47K |
| Inventory | $253K+614.4% | $35K | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.7M-44.6% | $13.9M+30.8% | $10.6M+6.9% | $9.9M+487.5% | $1.7M-74.3% | $6.6M+5.3% | $6.2M-69.8% | $20.7M |
| Current Liabilities | $7.6M-45.2% | $13.9M+31.3% | $10.6M+7.0% | $9.9M+484.6% | $1.7M-74.3% | $6.6M+5.3% | $6.2M+137.0% | $2.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$6.4M+44.4% | -$11.5M-19.2% | -$9.6M-20.9% | -$8.0M-416.4% | -$1.5M-98.9% | -$774K-38.8% | -$558K-14.0% | -$490K |
| Retained Earnings | -$27.3M-20.9% | -$22.6M-8.9% | -$20.7M-10.6% | -$18.7M-574.0% | -$2.8M+81.9% | -$15.4M-4.2% | -$14.8M-5.5% | -$14.0M |
ASBP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$928K+15.9% | -$1.1M+3.2% | -$1.1M+34.9% | -$1.8M-465.2% | $480K+196.8% | -$496K-781.1% | -$56K+70.9% | -$193K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
| Financing Cash Flow | -$17K-100.6% | $2.8M | $0-100.0% | $3.1M+728.3% | -$492K-200.0% | $492K+1624.3% | $29K-87.5% | $229K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
ASBP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 45.5% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -59015.8% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -95337.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -77.0%+123.3pp | -200.3% | N/A | N/A | -3.3%-1.8pp | -1.4%-0.3pp | -1.1% |
| Current Ratio | 0.170.0 | 0.17+0.1 | 0.09-0.1 | 0.20+0.1 | 0.09+0.1 | 0.01-0.0 | 0.06+0.0 | 0.02 |
| Debt-to-Equity | -1.210.0 | -1.21-0.1 | -1.10+0.1 | -1.25-0.2 | -1.10+7.4 | -8.49+2.7 | -11.18+31.1 | -42.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Aspire Biopharma Holdings Inc's annual revenue?
Aspire Biopharma Holdings Inc (ASBP) reported $6K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Aspire Biopharma Holdings Inc's gross margin?
Aspire Biopharma Holdings Inc (ASBP) had a gross margin of -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aspire Biopharma Holdings Inc's operating cash flow?
Aspire Biopharma Holdings Inc (ASBP) generated -$4.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aspire Biopharma Holdings Inc's total assets?
Aspire Biopharma Holdings Inc (ASBP) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aspire Biopharma Holdings Inc spend on research and development?
Aspire Biopharma Holdings Inc (ASBP) invested $924K in research and development during fiscal year 2025.
What is Aspire Biopharma Holdings Inc's current ratio?
Aspire Biopharma Holdings Inc (ASBP) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aspire Biopharma Holdings Inc's debt-to-equity ratio?
Aspire Biopharma Holdings Inc (ASBP) had a debt-to-equity ratio of -1.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aspire Biopharma Holdings Inc's cash runway?
Based on fiscal year 2025 data, Aspire Biopharma Holdings Inc (ASBP) had $1.0M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aspire Biopharma Holdings Inc's debt-to-equity ratio negative or unusual?
Aspire Biopharma Holdings Inc (ASBP) has negative shareholder equity of -$6.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is Aspire Biopharma Holdings Inc?
Aspire Biopharma Holdings Inc (ASBP) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.